drugset / Trial / NCT02042989
MLN9708 and Vorinostat in Patients With Advanced p53 Mutant Malignancies
NaSingle-groupOpen-labelTreatment
Summary
The goal of this clinical research study is to find the highest tolerable dose of the combination of MLN9708 and vorinostat that can be given to patients with advanced solid tumors. The safety of these drugs will also be studied.
Timeline
- Start
- 2014-06-27
- Primary completion
- 2020-01-22
- Completion
- 2020-01-22
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ixazomib | Unknown | 3 mg | Oral |
| Subject | Vorinostat | Small molecule | 100 mg | Oral |